Aktuellt
SENASTE
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annual growth rate of 54% for 2020–2024 in the opioid use disorder market, a still strong outlook and a blockbuster pipeline.
LÄS MER
